Trial Profile
A Phase IIa, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Human Mesenchymal Stem Cells to Subjects with Moderate Traumatic Brain Injury
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 May 2016
Price :
$35
*
At a glance
- Drugs Ischaemia-tolerant mesenchymal stem cells (Primary)
- Indications Traumatic brain injuries
- Focus Adverse reactions; Therapeutic Use
- Sponsors Stemedica Cell Technologies
- 24 May 2016 New trial record
- 18 May 2016 According to a Stemedica Cell Technologies media release, company has received an FDA IND approval for this trial.